Biomage

Biomage developed a cloud-based data analysis and visualization platform for single-cell RNA sequencing data. The company was founded in 2019 in Glasgow, United Kingdom, by Adam Kurkiewicz (CEO), Iva Babukova (CTO), and Vicky Morrison (CSO). Kurkiewicz, a bioinformatics researcher and software engineer, identified the need for more accessible single-cell data analysis tools.

The company’s core product was Cellenics, a software platform that enabled biologists and researchers without bioinformatics expertise to process, analyze, and visualize complex single-cell datasets. Cellenics was designed to significantly reduce analysis time from months to weeks by providing an interactive, user-friendly interface. The platform offered tools for quality control, data integration, differential gene expression analysis, and the generation of publication-quality figures. Biomage provided a free community instance of Cellenics for academic researchers, which grew to a user base of nearly 4,000 researchers globally. For commercial clients in the biotech and pharmaceutical sectors, Biomage offered customized and scalable end-to-end solutions.

Biomage raised a total of $1.51 million over three funding rounds from investors including IndieBio, SOSV, and Techstart Ventures. In January 2024, Biomage was acquired by Parse Biosciences, a provider of scalable single-cell sequencing solutions. As part of the acquisition, the Biomage team was integrated into Parse, and the Cellenics platform was rebranded as Trailmaker. The acquisition aimed to combine Biomage's analysis software with Parse's Evercode technology to provide researchers with a more powerful and streamlined single-cell analysis workflow.

Keywords: single-cell analysis, RNA sequencing, bioinformatics, data analysis software, Cellenics, transcriptomics, drug discovery, computational biology, genomics, data visualization, cell analysis, life sciences, biotech, academic research, pharmaceutical research, Parse Biosciences, Trailmaker, cloud analytics, gene expression